...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of clinical nutrition >Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes.
【24h】

Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes.

机译：辅酶Q10可改善血压和血糖控制：这是一项针对2型糖尿病患者的对照试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Our objective was to assess effects of dietary supplementation with coenzyme Q10 (CoQ) on blood pressure and glycaemic control in subjects with type 2 diabetes, and to consider oxidative stress as a potential mechanism for any effects. SUBJECTS AND DESIGN: Seventy-four subjects with uncomplicated type 2 diabetes and dyslipidaemia were involved in a randomised double blind placebo-controlled 2x2 factorial intervention. SETTING: The study was performed at the University of Western Australia, Department of Medicine at Royal Perth Hospital, Australia. INTERVENTIONS: Subjects were randomly assigned to receive an oral dose of 100 mg CoQ twice daily (200 mg/day), 200 mg fenofibrate each morning, both or neither for 12 weeks. MAIN OUTCOME MEASURES: We report an analysis and discussion of the effects of CoQ on blood pressure, on long-term glycaemic control measured by glycated haemoglobin (HbA(1c)), and on oxidative stress assessed by measurement of plasma F2-isoprostanes. RESULTS: Fenofibrate did not alter blood pressure, HbA(1c), or plasma F2-isoprostanes. There was a 3-fold increase in plasma CoQ concentration (3.4+/-0.3 micro mol/l, P<0.001) as a result of CoQ supplementation. The main effect of CoQ was to significantly decrease systolic (-6.1+/-2.6 mmHg, P=0.021) and diastolic (-2.9+/-1.4 mmHg, P=0.048) blood pressure and HbA(1c) (-0.37+/-0.17%, P=0.032). Plasma F2-isoprostane concentrations were not altered by CoQ (0.14+/-0.15 nmol/l, P=0.345). CONCLUSIONS: These results show that CoQ supplementation may improve blood pressure and long-term glycaemic control in subjects with type 2 diabetes, but these improvements were not associated with reduced oxidative stress, as assessed by F2-isoprostanes. SPONSORSHIP: This study was supported by a grant from the NH&MRC, Australia.
机译：目的：我们的目的是评估膳食补充辅酶Q10（CoQ）对2型糖尿病患者血压和血糖控制的影响，并将氧化应激作为任何作用的潜在机制。受试者与设计：74名无并发症2型糖尿病和血脂异常的受试者参与了随机双盲安慰剂对照2x2析因干预。地点：这项研究是在澳大利亚皇家珀斯医院西澳大利亚大学医学系进行的。干预措施：受试者被随机分配为每天两次口服口服剂量为100 mg CoQ（200 mg /天），每天早晨接受200 mg非诺贝特，两者都服用或不服用12周。主要观察指标：我们报告了辅酶Q对血压，通过糖化血红蛋白（HbA（1c））进行的长期血糖控制以及对通过血浆F2-异前列腺素的评估所产生的氧化应激的影响的分析和讨论。结果：非诺贝特没有改变血压，HbA（1c）或血浆F2-异前列腺素。补充辅酶Q可使血浆辅酶Q浓度增加3倍（3.4 +/- 0.3 micro mol / l，P <0.001）。辅酶Q的主要作用是显着降低收缩压（-6.1 +/- 2.6 mmHg，P = 0.021）和舒张压（-2.9 +/- 1.4 mmHg，P = 0.048）血压和HbA（1c）（-0.37 + / -0.17％，P = 0.032）。血浆F2-异前列腺素浓度不受CoQ的影响（0.14 +/- 0.15 nmol / l，P = 0.345）。结论：这些结果表明补充辅酶Q可以改善2型糖尿病患者的血压和长期血糖控制，但是这些改善与氧化应激的降低没有关系，如F2-异前列腺素所评估的。赞助：这项研究得到了澳大利亚NH＆MRC的资助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号